← back to search

Chengxing Lu

Novartis (Switzerland) · CH
Area of research
Ophthalmology · Radiology, Nuclear Medicine and Imaging
Research interest
Research focused on Aflibercept and Indacaterol, with related work in Salmeterol, Ranibizumab, Metastatic Urothelial Carcinoma. Notable publications include 'Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials', 'INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD', and 'FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 / 3 mRNA Expression'.
h-index
citations
467
works
6
NIH funding
primary concept
email

Recent publications

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
Journal of Clinical Oncology 2022cited by 91position: middledoi
Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies
Ophthalmology Retina 2018cited by 57position: middledoi
Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials
Ophthalmology 2016cited by 171position: middledoi
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
2015cited by 1position: middledoi
INSTEAD: a randomised switch trial of indacaterol <i>versus</i> salmeterol/fluticasone in moderate COPD
European Respiratory Journal 2014cited by 122position: middledoi
Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study
AIDS Research and Human Retroviruses 2013cited by 25position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paul Mitchell · The University of Sydney2 papers (2016–2018)Pablo Altman · Novartis (Switzerland)2 papers (2014–2015) · 2 papers (2014–2015) · 2 papers (2016–2018)Alberto Papi · Instituto de Investigación Sanitaria de Santiago2 papers (2014–2015)D. R. Young · University of Turku2 papers (2014–2015)Andrea Rossi · University of Padua2 papers (2014–2015)Matthew P. Quinn · Queen's University2 papers (2014–2015) · 2 papers (2014–2015)R. Cameron · Novartis (Switzerland)2 papers (2014–2015)Giovanni Staurenghi · University of Sheffield2 papers (2016–2018)Thys van der Molen · University of Aberdeen2 papers (2014–2015)Kathleen Squires · Thomas Jefferson University1 papers (2013–2013)Carola Metzig · Bayer (Germany)1 papers (2018–2018)Cora N. Sternberg · Cornell University1 papers (2022–2022)Florence Joly · Délégation Normandie1 papers (2022–2022)Karam Mounzer · Penn Presbyterian Medical Center1 papers (2013–2013)Sebastian M. Waldstein · Westmead Hospital1 papers (2016–2016)Anthony Rodgers · Tropical Population Health Unit1 papers (2013–2013)Keiko Nakajima · Johns Hopkins Medicine1 papers (2022–2022)